Drew Mellan New Director of Account Management of Noble

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Noble, an Aptar Pharma company, announced today that Drew Mellan has joined the team as director of account management. In this new position, Mellan will serve as the voice of the customer, communicating their goals and interests to Noble with the purpose of maximizing value for them.

Mellan has two decades of business development experience working with global pharmaceutical, industrial packaging, personal care and luxury fragrance companies. Most recently, he worked at Aptar Pharma, beginning in 2010 as a senior account manager where he successfully developed the company’s Consumer Health Care (CHC) business in North America. In 2015, he joined the Aptar GSK Global Account team. Under his guidance, GSK and Aptar Pharma partnered to launch the highly successful transition of Flonase from a prescription to an over-the-counter drug therapy, considered the “gold standard switch” by GSK and the industry.

Prior to joining Aptar Pharma, Mellan held business development management positions in the packaging industry with companies such as Sonoco Products Company, the world’s largest producer of composite cans, tubes and cores; and Qualipac America, a developer of packaging for the luxury beauty industry.

“This is a unique position for our business development team; one that places emphasis on building personal relationships to meet the needs of our existing clients and maximize our value to them,” explained Noble CEO Jeff Baker. “Drew’s overarching role is to understand and communicate our customers’ goals and interests so that Noble can leverage our expertise and best practices and identify products and core services that address their challenges.”

Mellan holds a Bachelor of Science in Finance from Rowan University in New Jersey.




Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.